Melatonin decreases levels of S100β and NFκ B, increases levels of synaptophysinina rat model of Alzheimer's disease

Current Aging Science

Volumn 6, Issue 2, 2013, Pages 142-149

  Jun, Zhou ^a   Li, Zhou ^a   Fang, Wang ^a   Fengzhen, Yang ^a   Puyuan, Wen ^b   Wenwen, Li ^a   Zhi, Song ^a   Bondy, Stephen C ^c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Central South University   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Amyloid; Hippocampus; Learning; Melatonin; NF B

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELATONIN; PROTEIN S100B; SYNAPTOPHYSIN; AMYLOID BETA PROTEIN[1-42]; NEURON SPECIFIC NUCLEAR PROTEIN;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; BRAIN CORTEX; CELL COUNT; CONTROLLED STUDY; DISEASE COURSE; ELECTRIC SHOCK; HIPPOCAMPUS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; WESTERN BLOTTING; ANIMAL TISSUE; ELECTRIC CURRENT; HIPPOCAMPAL CA3 REGION; NERVE CELL; Y-MAZE TEST;

EID: 84882785429     PISSN: 18746098     EISSN: 18746128     Source Type: Journal    
DOI: 10.2174/18746098112059990005     Document Type: Article

References (57)

1. Annaert WG, Levesque L, Craessaerts K, et al. Presenilin 1 controls gamma-secretase processing of amyloid precursor protein in pre-golgi compartments of hippocampal neurons. J Cell Biol 1999; 147: 277-94.
2. Esteras-Chopo A, Pastor MT, Serrano L, Lopez de la Paz M. New strategy for the generation of specific D-peptide amyloid inhibitors. J Mol Biol 2008; 377: 1372-81.
3. Wu Q, Combs C, Cannady SB, Geldmacher DS, Herrup K. Betaamyloid activated microglia induce cell cycling and cell death in cultured cortical neurons. Neurobiol Aging 2000; 21: 797-806.
4. Sotthibundhu A, Sykes AM, Fox B, Underwood CK, Thangni-pon W, Coulson EJ. Beta-amyloid(1-42) induces neuronal death through the p75 neurotrophin receptor. J Neurosci 2008; 28: 3941-6.
5. Miranda S, Opazo C, Larrondo LF, et al. The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer's disease. Prog Neurobiol 2000; 62: 633-48.
6. Cuevas E, Limon D, Perez-Severiano F, Diaz A, Ortega L, Zenteno E, Guevara J. Antioxidant effects of epicatechin on the hippocampal toxicity caused by amyloid-beta 25-35 in rats. Eur J Pharmacol 2009; 616: 122-7.
7. Han M, Liu Y, Tan Q. Therapeutic efficacy of stemazole in a betaamyloid injection rat model of Alzheimer's disease. Eur J Pharmacol 2011; 657: 104-10.
8. Perry G, Castellani RJ, Hirai K, Smith MA. Reactive oxygen species mediate cellular damage in Alzheimer disease. J Alzheimers Dis 1998; 1: 45-55.
9. Pike CJ, Ramezan-Arab N, Cotman CW. β Amyloid neurotoxicity in vitro: evidence of oxidative stress but not protection by antioxidants. J Neurochem 1997; 69: 1601-11.
10. Zhang JM, Wu MN, Qi JS, Qiao JT. Amyloid beta-protein ragment 31-35 suppresses long-term potentiation in hippocampal CA1 region of rats in vivo. Synapse 2006; 60: 307-13.
11. Arendt, J. Melatonin, circadian rhythms and sleep. New Engl J Med 2000; 343: 1114-6.
12. Tricoire H, Locatelli A, Chemineau P, Malpaux B. Melatonin enters the cerebrospinal fluid through the pineal recess. Endocrinology 2002; 143: 84-90.
13. Esquifino AI, Pandi-Perumal SR, Cardinali DP. Circadian organization of the immune response: A role for melatonin. Clin Appl Immunol Rev 2004; 4: 423-33.
14. Guerrero JM, Reiter RJ. Melatonin-immune system relation-ships. Curr Top Med Chem 2002; 2: 167-79.
15. Bedrosian TA, Herring KL, Weil ZM, Nelson RJ. Altered temporal patterns of anxiety in aged and amyloid precursor protein (APP) transgenic mice. Proc Natl Acad Sci USA 2011; 108(28): 11686-91.
16. Burkhardt S, Reiter RJ, Tan DX, Hardeland R, Cabrera J, Karbownik M. DNA oxidatively damaged by chromium(III) and H(2)O(2) is protected by the antioxidants melatonin, N(1)-acetyl- N(2)-formyl-5-methoxykynuramine, resveratrol and uric acid. Int J Biochem Cell Biol 2001; 33: 775-83.
17. Galano A, Tan DX, Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51: 1-16.
18. Hardeland R, Pandi-Perumal, SR. Melatonin, a potent agent in antioxidative defense: Actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nutr Metab (Lond) 2005; 2: 22.
19. Sharman EH, Bondy SC, Sharman KZ, Lahiri D, Cotman CW, Perreau VM. Effects of melatonin and age on gene expression in mouse CNS using microarray analysis. Neurochem Internat 2007; 50: 336-44.
20. Sharman KG, Sharman EH, Yang E, Bondy SC. Dietary melatonin selectively reverses age-related changes in cortical cytokine mRNA levels, and their responses to an inflammatory stimulus. Neurobiol Aging 2002; 23: 633-8.
21. Pappolla MA, Sos M, Omar RA, et al. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 1997; 17: 1683-90.
22. Lahiri DK, Chen D, Ge, YW, Bondy SC, Sharman E.H. Dieta-ry supplementation with melatonin reduces levels of amyloid betapeptides in the murine cerebral cortex J Pineal Res 2004a; 36: 224-31.
23. Shen YX, Xu SY, Wei W, Wang XL, Wang H, Sun X. Melato-nin blocks rat hippocampal neuronal apoptosis induced by amyloid beta-peptide 25-35. J Pineal Res 2002; 32: 163-7.
24. Ng KM, Lau CF, Fung ML. Melatonin reduces hippocampal betaamyloid generation in rats exposed to chronic intermittent hypoxia Brain Res 2010; 1354: 163-71.
25. Ishibashi K, Tomiyama T, Nishitsuji K, Hara M, Mori H. Absence of synaptophysin near cortical neurons containing oligomer Abeta in Alzheimer'sdisease brain. J Neurosci Res 2006; 84: 632-6.
26. Reddy PH, Mani G, Park BS, et al. Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J Alzheimers Dis 2005; 7: 103-17.
27. Daly C, Sugimori M, Moreira JE, Ziff EB, Llinas R. Synaptophysin regulates clathrin-independent endocytosis of synaptic vesicles. Proc Natl Acad Sci USA 2000; 97: 6120-5.
28. Counts SE, Nadeem M, Lad SP, Wuu J, Mufson EJ. Differen-tial expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. J Neuropath Exp Neurol 2006; 65: 592-601.
29. Adalbert R, Nogradi A, Babetto E, et al. Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies. Brain 2009; 132 (Pt 2): 402-16.
30. Williams PA, Thirgood RA, Oliphant H, et al. Retinal ganglion cell dendritic degeneration in a mouse model of Alzheimer's disease. Neurobiol Aging 2013; 34:1799-806.
31. Gius D, Botero A, Shah S, Curry HA. Intracellular oxidation/ reduction status in the regulation of transcription factors NFkappaB and AP-1. Toxicol Lett 1999; 106: 93-106.
32. Mori T, Koyama N, Arendash GW, Horikoshi-Sakuraba Y, Tan J, Town T. Overexpression of human S100β exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease. Glia 2010; 58: 300-14.
33. Mrak RE, Griffin WS. The role of activated astrocytes and of the neurotrophic cytokine S100β in the pathogenesis of Alzheimer's disease. Neurobiol Aging 2001; 22: 915-22.
34. Iourov IY, Vorsanova SG, Yurov YB. Genomic landscape of the Alzheimer's disease brain: chromosome instability--aneuploidy, but not tetraploidy--mediates neurodegeneration. Neurodegener Dis 2011; 8: 35-7.
35. Streit WJ. Microglia and Alzheimer's disease pathogenesis, J Neurosci Res 2004; 77: 1-8.
36. Bondy SC, Yang YE, Walsh TJ, Gie YW, Lahiri DK. Dietary modulation of age-related changes in cerebral pro-oxidant status. Neurochem Int 2002; 40: 123-30.
37. Cuzzocrea S, Costantino G, Gitto E, et al. Protective effects of melatonin in ischemic brain injury. J Pineal Res 2000; 29: 217-27.
38. Kotler M, Rodriguez C, Sainz RM, Antolin I, Menendez-Pelaez A. Melatonin increases gene expression for antioxidant enzymes in rat brain cortex. J Pineal Res 1998; 24: 83-9.
39. Lezoualch F, Sparapani M, Behl C. N-acetyl-serotonin (normelatonin) and melatonin protect neurons against oxidative challenges and suppress the activity of the transcription factor NF-kappaB. J Pineal Res 1998; 24: 168-78.
40. Sharman EH, Vaziri ND, Ni Z, Sharman KZ, Bondy SC. Reversal of biochemical and behavioral parameters of brain aging by melatonin and acetyl L-carnitine. Brain Res 2002; 95 223-30.
41. Nava F, Carta G. Melatonin reduces anxiety induced by lipopolysaccharide in the rat. Neurosci Lett 2001; 307: 57-60.
42. Sharman EH, Sharman KZ, Bondy SC. Melatonin causes gene expression in aged animals to respond to inflammatory sti-muli in a manner differing from that of young animals. Curr Aging Sci 2008; 1: 152-8.
43. Korkmaz A, Reiter RJ, Topal T, Manchester LC, Oter S, Tan DX. Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med 2009; 15: 43-50.
44. Clapp-Lilly KL, Smith MA, Perry G, Duffy LK. Melatonin reduces interleukin secretion in amyloid-beta stressed mouse brain slices. Chem Biol Interact 2001; 134: 101-7.
45. Masilamoni JG, Jesudason EP, Dhandayuthapani S, et al. The neuroprotective role of melatonin against amyloid beta peptide injected mice. Free Radic Res 2008; 42: 661-73.
46. Acuna-Castroviejo D, Martin M, Macias M, et al. Melatonin, mitochondria, and cellular bioenergetics. J Pineal Res 2001; 30: 65-7.
47. Zatta P, Tognon G, Carampin P. Melatonin prevents free radical formation due to the interaction between beta-amyloid peptides and metal ions [Al(III), Zn(II), Cu(II), Mn(II), Fe(II)]. J Pineal Res 2003; 35: 98-103.
48. Feng Z, Chang Y, Cheng Y, et al. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J Pineal Res 2004; 37: 129-36.
49. Feng Z, Zhang JT. Protective effect of melatonin on beta-amyloidinduced apoptosis in rat astroglioma C6 cells and its mechanism. Free Radic Biol Med 2004; 37: 1790-1801.
50. Bondy SC, Sharman EH. Melatonin, oxidative stress and the aging brain. In: Oxidative Stress. In: Bondy SC, Maiese K. (eds.) Basic Research and Clinical Practice: Aging and Age-Related Disorders, Humana Press, Totowa NJ 2010; pp. 339-57.
51. Giunta B, Fernandez F, Nikolic WV, et al. Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflammation 2008; 5: 51.
52. Yu WH, Go L, Guinn BA, Fraser PE, Westaway D, McLaurin J. Phenotypic and functional changes in glial cells as a function of age. Neurobiol Aging 2002; 23: 105-15.
53. Griffin WS. Inflammation and neurodegenerative diseases. Am J Clin Nutr 2006; 83: 470S-4S.
54. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies. Neurobiol Aging 2007; 28: 639-47.
55. Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 2003; 35: 125-30.
56. Bondy SC, Sharman EH. Melatonin and the aging brain. Neurochem Int 2007; 50: 571-80.
57. Lahiri DK, Ge YW, Sharman EH, Bondy SC. Age-related changes in serum melatonin in mice, higher levels of combined melatonin and melatonin sulfate in the brain cortex than serum, heart, liver and kidney tissues. J Pineal Res 2004b; 36: 217-23.